Analyst Price Target is $1.25
▲ +53.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Athersys in the last 3 months. The average price target is $1.25, with a high forecast of $1.25 and a low forecast of $1.25. The average price target represents a 53.19% upside from the last price of $0.82.
Current Consensus is
The current consensus among 1 polled investment analysts is to hold stock in Athersys. This rating has held steady since October 2021, when it changed from a Buy consensus rating.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.